Agilent Technologies and Sera Prognostics Enter Strategic Partnership to Develop Proteomic Assays for Fetal and Maternal Health

  Agilent Technologies and Sera Prognostics Enter Strategic Partnership to
  Develop Proteomic Assays for Fetal and Maternal Health

Business Wire

SANTA CLARA, Calif. & SALT LAKE CITY -- February 12, 2013

Agilent Technologies Inc. (NYSE: A) and Sera Prognostics Inc., a women’s
health company, today announced a strategic partnership to develop proteomic
assays for the early prediction of pregnancy complications.

Sera Prognostics is currently developing a novel test for the early prediction
of preterm birth risk using advanced proteomic science. Agilent is a leading
provider of a wide range of analytical instrumentation, including liquid
chromatography, mass spectrometry and automation systems.

“By providing pivotal information to physicians, Sera’s preterm birth
predictor is designed to address an unmet medical need for a reliable, early
risk assessment that has the potential to help significantly improve the
health of mothers and newborns, while materially reducing the costs of care,”
said Gregory C. Critchfield, M.D., M.S., chairman and chief executive officer
of Sera Prognostics. “Our partnership with Agilent provides Sera with access
to advanced and innovative technologies designed to deliver on the promise of
personalized medicine.”

“Agilent and Sera Prognostics share the vision of applying the power of
advanced proteomic technologies to address meaningful medical challenges,”
said Yvonne Linney, VP and general manager of Agilent’s Life Science Solutions
Division. “Agilent instrumentation is at the forefront of driving
high-throughput workflows for sample preparation and mass-spec analysis that
is critical in the field of proteomics.”

As part of the partnership, Sera Prognostics purchased multiple Agilent 1290
Infinity ultra high-performance liquid chromatography systems, 6490 iFunnel
triple quadrupole mass spectrometry systems and 1260 Infinity LC systems with
ultraviolet detectors and is adapting Agilent’s automated sample-preparation
technologies for production.

The partners will develop high-throughput workflows for sample preparation and
mass-spectrometry analysis. To meet the demands of high-volume testing, Sera
Prognostics expects to leverage Agilent’s novel automated sample-prep
technology and other automation, including the AssayMAP Bravo and RapidFire
fast liquid chromatography together with ultra-sensitive ion funnel triple
quadrupole mass spectrometry.

About Sera Prognostics, Inc.

Sera Prognostics is a private biotechnology company developing novel
diagnostic tests designed for the early prediction of preterm birth and other
pregnancy complications, so that personalized, effective care can be given.
These innovative tests have the potential of improving the health of both
mothers and infants. In November 2011, Sera completed a Series A financing
round of $19.3 million to develop its ProNid preterm birth predictor. The
company has assembled a strong management team and board of directors with
significant clinical development and women's health-care diagnostic
experience. Sera is currently completing the world’s largest clinical
biomarker study focused on the validation of its ProNid test for predicting
the risk of preterm birth. Sera is located in Salt Lake City, Utah. For more
information, visit www.seraprognostics.com.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company
and a technology leader in chemical analysis, life sciences, diagnostics,
electronics and communications. The company’s 20,500 employees serve customers
in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal
2012. Information about Agilent is available at www.agilent.com.

NOTE TO EDITORS: Further technology, corporate citizenship and executive news
are available at www.agilent.com/go/news.

Contact:

Agilent
Eric Endicott, +1 408 553 2005
eric_endicott@agilent.com
or
Sera Prognostics, Inc.
Andrew Sauter, CFO, + 801 990-0772
info@seraprognostics.com
or
Continuum Health Communications, for Sera
Terri Clevenger, + 203 856-4326
tclevenger@continuumhealthcom.com